2-(3-((4,5,7-TRIFLUOROBENZO[D]THIAZOL-2-YL)METHYL)-1H-INDOL-1-YL)ACETIC ACID, 95.0%, 100mg

5-Bromo-N,N-diethylpyridine-3-sulfonamide, 95.0%, 1g

1-(2-Methoxyethyl)-5-oxopyrrolidine-3-carboxylic acid, 95.0%, 1g

N-(2-Hydroxyethyl)acrylamide (stabilized with MEHQ)>98.0%(GC)(T)500g

C-[5-(4-Trifluoromethoxy-phenyl)-[1,3,4]oxadiazol-2-yl]-methylamine; hydrochloride, 95.0%, 1g

(S)-3-((((9H-FLUOREN-9-YL)METHOXY)CARBONYL)AMINO)-4-(4-CYANOPHENYL)BUTANOIC ACID, 95%, 1g

2-CYANO-4-CYCLOPROPYL-1H-IMIDAZOLE HYDROCHLORIDE, 95.0%, 5g

2-desoxi-D-ribosa, mínimo 99 %, para bioquímica, 5 g, envase de vidrio

1-(3-Fluorobenzyl)-1H-pyrazole-4-carboxylic acid, 1g

2-Phenylcyclohexanone>98.0%(GC)5g

(4S,5R)-5-(3,5-Bis(trifluoromethyl)phenyl)-4-methyloxazolidin-2-one, 95.0%, 10g

3-Nitro-[1,1'-biphenyl]-4-carboxylic acid, 98%, 5g

5-Phenyloxazolidine-2,4-dione, 97%, 250mg